Register for our free email digests:
Division of Leap Therapeutics Inc.
Latest From KuDOS Pharmaceuticals Ltd.
Five and a half years after its decision to spin off its pharmaceutical business and a year and a half away from having the US Supreme Court break its monopoly on BRCA gene testing, Myriad Genetics is no longer an exception among molecular diagnostics companies. It must find its way along a more crowded path.
Singapore’s MerLion Completes Phase III Finafloxacin Studies For Outer Ear Infection, Looks Ahead To Other Indications
Singapore-based MerLIon Pharmaceuticals has reached another milestone with its finafloxacin antibiotic with the topic form for outer ear infection successfully passing Phase III trials in North America. But the firm is still looking for help taking another indication into Phase III.
By licensing MK-1775 from Merck, AstraZeneca underscores the key strategic role DNA damage response will play in the U.K. drug maker’s attempts to build oncology into a growth engine.
Financings Of The Fortnight Sees New Biotech Funding All Over The Globe, And Without Much VC Participation
Plus news on recent financial activity by Merrimack, Promethera, ADC Therapeutics and Enterome Bioscience.
- Gene Therapy, Cell Therapy
- Medical Devices
- Therapeutic Areas
- Wound Healing & Tissue Repair
- Middle East
- Parent & Subsidiaries
- Leap Therapeutics Inc.
- Senior Management
Nissim Mashiach, Pres. & CEO
Mark Page, CFO
Adi Zuloff-Shani, PhD, VP, Dev.
- Contact Info
Phone: 3 9235556
25 Sivim St.
Petach Tikva, 49517
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.